Edit Symbol List
Don't know the stock symbol? Use the
Symbol Lookup tool.
Alphabetize the sort order of my symbols
Investing just got easier…
ETFs with MNKD as a Top 10 Holding*
|Weighting||ETF Name (Symbol)||100-Day Price Change (%)|
|0%||BioShares Biotechnology Products Fund (BBP)||+6.08 (22.96%)|
Company Description (as filed with the SEC)
Unless the context requires otherwise, the words "MannKind," "we," "company," "us" and "our" refer to MannKind Corporation and its subsidiaries. MannKind Corporation is a biopharmaceutical company focused on the discovery and development of therapeutic products for diseases such as diabetes. Our only approved product, AFREZZA, is a rapid-acting inhaled insulin that was approved by the U.S. Food and Drug Administration (the "FDA") on June 27, 2014 to improve glycemic control in adult patients with diabetes. According to the Centers for Disease Control and Prevention, in the United States in 2012, approximately 29.1 million people had diabetes. Globally, the International Diabetes Federation has estimated that approximately 387.0 million people had diabetes in 2014 and approximately 592.0 million people will have diabetes by 2035. AFREZZA is a rapid-acting, inhaled insulin used to control high blood sugar in adults with type 1 and type 2 diabetes. ... More ...
Where does MNKD fit in the risk graph?
|Annual EPS Est:||$-0.51|
|Quarterly EPS Est:||-0.08|